Key facts
- This page summarizes Patrick Lamy's Form 4 filing for Akero Therapeutics, Inc. (AKRO).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 18 Dec 2024, 21:03.
Patrick Lamy - 16 Dec 2024 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)
- Reporting relationship
- Senior VP, Commercial Strategy
- Issuer ticker
- AKRO
- Reported as of
- 16 Dec 2024
- Net transaction value
- -$29,130
- SEC form
- 4
- Accepted by SEC
- 18 Dec 2024, 21:03:48 UTC
- Prior SEC filing
- 12 Dec 2024
- Next SEC filing
- 29 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jonathan Young
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Patrick Lamy filed Form 4 for Akero Therapeutics, Inc. (AKRO) on 18 Dec 2024.
Change
- Previous filing in this sequence was filed on 12 Dec 2024.
- Current net transaction value: -$29,130.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AKRO
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +17,400
- Change %
- +97%
- Price
- $0.000000
- Shares after
- 35,258
- Date
- 16 Dec 2024
- Ownership
- Direct
- Footnotes
- F1
AKRO
transaction
Common Stock
Sale
- Transaction value
- $29,130
- Shares
- -1,000
- Change %
- -2.8%
- Price
- $29.13
- Shares after
- 34,258
- Date
- 16 Dec 2024
- Ownership
- Direct
- Footnotes
- F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AKRO
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +52,100
- Change %
- Price
- $0.000000
- Shares after
- 52,100
- Date
- 16 Dec 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 52,100
- Exercise price
- $29.23
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 4 footnotes
Footnote F1
These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in eight (8) equal semi-annual installments, commencing from December 16, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
Footnote F2
The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 28, 2024, previously adopted by the Reporting Person.
Footnote F3
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.97 to $29.53, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
Footnote F4
This option shall vest and become exercisable in forty-eight (48) equal monthly installments, commencing from December 16, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.